We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Regeneron is a leading biotechnology company that invents medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments, almost all of which were homegrown in our laboratories.
Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergy immunotherapy products and services. At Stallergenes Greer, we operate to sustain growth and create value for society as a whole. With a history of innovation, Stallergenes Greer has always endeavoured to offer new treatment options to meet the needs of patients and to consolidate its knowledge and expertise in the field of innovative treatments with a view to developing products that seek to optimise treatment and management of patients with allergies. The company’s strategy is based on three pillars: precision medicine for better patient care, investing in our people and a high-performance agile organisation.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com
At Menarini Asia-Pacific, we are dedicated to improving people's lives. We believe that good health empowers people to unlock their full potential. Strengthened by Menarini's illustrious heritage since 1886 and a network of global partners, Menarini Asia-Pacific today serves over 13 key markets in the region - invigorating lives of the people and communities where we serve.
Viatris is a global pharmaceutical company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®
Danone Nutricia Campus is a non-profit foundation co-founded by Danone and world-leading nutrition experts with the mission to offer an open science education platform for healthcare professionals.
The platform grants free access to the latest science in nutrition, health and patient care to support knowledge discovery and skill development of healthcare professionals with a wide range of expert learning resources and accredited education developed for a global audience.
Dear Friends and Colleagues,
Our specialty is evolving. Allergic diseases and asthma are a rapidly growing health problem worldwide with a marked socio-economic impact. Alongside the rapid environmental (climate change, pollution, etc) and lifestyle changes, the fast-evolving economies of Asia-Pacific face the major brunt of the burden of allergic diseases. Parallel to this are the advances in scientific evidence, epidemiological and epigenetic characteristic of the region.
The Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) and Philippine Society of Allergy, Asthma and Immunology (PSAAI) will host the APAAACI 2022 Congress PSAAI@50 on the 5th – 8th of December 2022 in Manila, Philippines. The theme of the Congress is ‘Evidence Based Integrated Care in Allergy, Asthma and Immunology: The New Frontiers’.M.
The scientific program will be a well-woven combination of the most recent advances and practical clinical aspects in allergy asthma and clinical immunology targeting both clinicians and researchers across specialties working in this space. With key international, regional, and national opinion leaders this will be a strikingly unique platform for leaders, colleagues and junior members. It will also be a unique platform for the best scientific exchange, networking and future collaborations. Our ultimate goal is to provide knowledge on the best practice parameters and the cutting edge advances in the treatment and prevention of Allergies, Asthma and Immunologic Diseases.
On behalf of the APAAACI and PSAAI, we welcome our industry partners to be part of this Congress. Your support will play an integral part to make the Congress a scientifically rewarding event for all those who participate.
Let’s make the APAAACI 2022 Congress PSAAI@50 a success! We look forward to your involvement!
Prof. Ruby Pawankar
Congress Chair President, APAAACI
Prof. Rommel Lobo
Congress Co-Chair President, PSAAI